Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 12 April 2021, 12:16 HKT/SGT

Source: Eisai
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021

TOKYO, Apr 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021.

ISNTD Festival is an annual event aiming to increase awareness about neglected tropical diseases (NTDs) and this year marks the 5th ISNTD Festival. At the ISNTD Festival Awards, which accompanies this festival, outstanding projects will be selected and awarded in each of the seven categories of animation, app, art, awareness campaign, mass media, photo, and video, related to NTDs.

The award-winning animation "Leave No One Behind" features the 10-year LF elimination activities of Eisai and its global partners which have been implemented since Eisai signed a joint statement with the World Health Organization (WHO) for the LF elimination in 2010. The animation highlights the feelings, thoughts and sufferings of patients which were perceived through activities for free provision of medicines and disease awareness. In addition, the animation highlights tremendous efforts of global partners including Eisai dedicated for drug delivery to remote regions, disease awareness activities for residents in endemic regions and support for mass drug administrations (MDAs), in order to make necessary medicines available to those who need them.

Eisai has been manufacturing diethylcarbamazine (DEC tablets), one of the LF treatments, at its Vizag Plant in India and has been providing to LF endemic countries for free since 2013. We have provided 2.01 billion DEC tablets to 28 countries and contributed to LF elimination in Egypt, Kiribati, Thailand and Sri Lanka. We have also been collaborating with global partners on disease awareness for LF and support for implementation of MDAs necessary for the LF elimination. Eisai announced to continue providing DEC tablets for free to endemic countries that need DEC until LF is eliminated in these countries.

By accelerating the development of new medicines for infectious diseases and NTDs including LF which are endemic in developing and emerging countries via leveraging partnerships, together with implementing activities to improve access to medicines including raising disease awareness locally and implementing price setting models that take income levels into account, Eisai strives to further contribute to increasing the benefits for patients and their families worldwide.

Media Inquiries:
Public Relations Department
Eisai Co., Ltd.

Topic: Press release summary
Source: Eisai

Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2021 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

July 23, 2021 08:17 HKT/SGT
Eisai: FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
July 21, 2021 09:34 HKT/SGT
Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer's Disease and Dementia at AAIC 2021
July 19, 2021 08:03 HKT/SGT
Eisai Launchs Bile Acid Transporter Inhibitor Goofice in Thailand
July 1, 2021 10:43 HKT/SGT
Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong
June 24, 2021 11:00 HKT/SGT
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)
June 23, 2021 14:20 HKT/SGT
Anticancer Agent "Tazverik Tablets 200mg" (Tazemetostat Hydrobromide) Approved In Japan For EZH2 Gene Mutation-positive Follicular Lymphoma
June 18, 2021 14:02 HKT/SGT
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai's MORAb-202 Antibody Drug Conjugate
June 15, 2021 08:00 HKT/SGT
Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
June 9, 2021 12:44 HKT/SGT
Eisai Receives Special Prize at Platinum Career Award 2021
June 9, 2021 10:31 HKT/SGT
Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)
More news >>
 News Alerts
Copyright © 2021 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: